Clinical insights

Key research benefits

Eli Lilly's investigational triple hormone agonist (GLP-1 + GIP + glucagon) — the only compound in this category with large-scale Phase 2/3 human trial data.

  • 28.7% average body weight loss at 68 weeks — the largest weight-loss result of any obesity drug tested to date (Phase 3 TRIUMPH-4, Dec. 2025).
  • 82–86% relative liver fat reduction at 24 weeks in a dedicated fatty-liver-disease sub-study — the most dramatic liver fat result ever recorded in a drug trial.
  • Up to 2.0% HbA1c reduction and 75.8% reduction in knee osteoarthritis pain (WOMAC score) as secondary benefits alongside weight loss.

Research backing

Jastreboff et al., NEJM 2023 (Phase 2, n=338); Sanyal et al., Nature Medicine 2024 (liver fat sub-study); TRIUMPH-4 Phase 3 (2025, n=5,800+ program-wide). Not yet FDA approved — submission expected late 2026/2027.

Research Grade Formula

Retatrutide

Fat Loss & Metabolic Health

Triple Agonist · 10mg

4.9 (312 reviews)

$115

Express Shipping $20 — Australia only

  • Third-party tested
  • Non-GMO
  • GMP certified
How to use

Follow research handling and reconstitution guidance for this compound. Always use appropriate lab technique and sterile materials.

Research Dosage Protocol
What's inside

Inside is Retatrutide, a multi-agonist research peptide studied for metabolic pathway signaling. The material is freeze-dried to preserve integrity until reconstituted for laboratory protocols.

Technical overview

  • Contents: Retatrutide research peptide, 10 mg class vial
  • Profile: Triple-agonist peptide for metabolic research models
  • Purity: ≥99% HPLC-validated research material
  • Appearance: White to off-white lyophilized solid
  • Solubility: Aqueous reconstitution with bacteriostatic water
  • Documentation: Batch COA available for quality confirmation

Reconstitute with bacteriostatic water at room temperature. For laboratory research and educational use only — not for human consumption.

Customer reviews

4.9

Based on 312 reviews